ARQT
Arcutis Biotherapeutics, Inc.
Biotechnology · Healthcare · United States
31.97
close · 2026-10-29
value
26
cheaper than peers26
quality
73
stronger fundamentals73
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
caveat margins at their own peak
Value inputs
| measure | company | vs peers |
| price to sales | 8.16× | 61 |
| cash flow yield, latest year | -0.5% | 50 |
| cash flow yield, 1 year ago | -3.6% | 50 |
| earnings yield, latest year | -0.5% | 50 |
| cash flow yield, 2 years ago | -7.5% | 41 |
| earnings yield, 1 year ago | -4.4% | 41 |
| forward P/E | 23.89× | 39 |
| earnings yield, 3 years ago | -21.6% | 23 |
| earnings yield, 2 years ago | -14.4% | 23 |
| cash flow yield, 3 years ago | -8.5% | 23 |
| price to book | 18.21× | 11 |
| EV to EBITDA | 573.92× | 3 |
12 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -1.4% | 80 |
| operating margin | -8.6% | 73 |
| revenue growth | 60.1% | 70 |
| debt to equity | 60.5% | 28 |
4 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | $3.5M |
| employees | 354 |
| first trade | 2020-01-31 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.13 | -1.16 | -3.78 | -5.66 |
| free cash flow | -$16.3M | -$117.3M | -$247.5M | -$281.0M |
| net income | -$16.1M | -$140.0M | -$262.1M | -$311.5M |
| revenue | $376.1M | $196.5M | $59.6M | $3.7M |